SLC3A1 — Solute Carrier Family 3 Member 1

SLC3A1 — Solute Carrier Family 3 Member 1

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">slc3a1</th>
</tr>
<tr>
<td class="label">Transporter</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">LAT1</td>
<td>SLC7A5</td>
</tr>
<tr>
<td class="label">y+LAT1</td>
<td>SLC7A7</td>
</tr>
<tr>
<td class="label">ASC1</td>
<td>SLC7A10</td>
</tr>
<tr>
<td class="label">xCT</td>
<td>SLC7A11</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">SLC7A9 (b^0,+AT)</td>
<td>Disulfide bond</td>
</tr>
<tr>
<td class="label">SLC7A13 (KAT-1)</td>
<td>Disulfide bond</td>
</tr>
<tr>
<td class="label">4F2hc (SLC3A2)</td>
<td>Homology</td>
</tr>
<tr>
<td class="label">Renal luminal AA</td>
<td>Substrate</td>
</tr>
<tr>
<td class="label">Na^+</td>
<td>Cotransport</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Introduction

SLC3A1 — Solute Carrier Family 3 Member 1

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">slc3a1</th>
</tr>
<tr>
<td class="label">Transporter</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">LAT1</td>
<td>SLC7A5</td>
</tr>
<tr>
<td class="label">y+LAT1</td>
<td>SLC7A7</td>
</tr>
<tr>
<td class="label">ASC1</td>
<td>SLC7A10</td>
</tr>
<tr>
<td class="label">xCT</td>
<td>SLC7A11</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">SLC7A9 (b^0,+AT)</td>
<td>Disulfide bond</td>
</tr>
<tr>
<td class="label">SLC7A13 (KAT-1)</td>
<td>Disulfide bond</td>
</tr>
<tr>
<td class="label">4F2hc (SLC3A2)</td>
<td>Homology</td>
</tr>
<tr>
<td class="label">Renal luminal AA</td>
<td>Substrate</td>
</tr>
<tr>
<td class="label">Na^+</td>
<td>Cotransport</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Introduction

SLC3A1 (Solute Carrier Family 3 Member 1) encodes the heavy chain subunit rBAT (related to B^0 amino acid transporter), which partners with a light chain to form the heteromeric amino acid transporter (HAT) system. Located on chromosome 2p16.3 (NCBI Gene ID: 10251, OMIM: 104614, Ensembl: ENSG00000166391, UniProt: Q07817), SLC3A1 is primarily expressed in the kidney and intestinal epithelium where it mediates reabsorption of cystine and dibasic amino acids [@palacin2005].

Mutations in SLC3A1 cause type I cystinuria, a disorder characterized by impaired cystine reabsorption in the kidney, leading to cystine stone formation. While SLC3A1 is not classically considered a neurodegeneration gene, amino acid transport across the blood-brain barrier and within neurons is critically important for neuronal function, and transport system dysfunction may contribute to neurodegenerative processes [@chillaron2011].

Gene Structure and Protein Architecture

Gene Organization

The SLC3A1 gene spans approximately 15 kb on chromosome 2p16.3 and consists of 8 exons encoding a 683-amino acid protein. The gene exhibits typical housekeeping gene features with multiple transcription start sites.

Protein Structure

The rBAT protein (79 kDa) is a type II membrane glycoprotein with:

• N-terminal extracellular domain (aa 1-480): Contains multiple N-linked glycosylation sites and the substrate binding interface
• Single transmembrane helix (aa 481-503): Anchors the protein in the plasma membrane
• C-terminal intracellular domain (aa 504-683): Contains trafficking signals and interacts with light chain subunits

The Heteromeric Amino Acid Transporter System

System Organization

Heteromeric amino acid transporters (HATs) consist of:

• Heavy chain (SLC3 family): rBAT (SLC3A1) or 4F2hc (SLC3A2) — provides extracellular domain and disulfide bond formation
• Light chain (SLC7 family): Determines substrate specificity and transport mechanism

Substrate Specificity

The SLC3A1/SLC7A9 heterodimer (system b^0,+) transports:

• Cystine: The oxidized dimer of cysteine
• Dibasic amino acids: Lysine, ornithine, arginine
• Some neutral amino acids: Leucine, isoleucine, phenylalanine

Tissue Distribution

SLC3A1 expression is predominantly localized to:

• Proximal renal tubule: Apical membrane of S1-S2 segments
• Small intestine: Apical membrane of enterocytes
• Placenta: Fetal membrane expression
• Low expression in other tissues

SLC3A1 in Kidney Function

Proximal Tubule Reabsorption

SLC3A1-mediated transport is critical for renal amino acid handling:

Apical uptake: The SLC3A1/SLC7A9 heterodimer localizes to the apical membrane of proximal tubular cells, where it reabsorbs filtered amino acids from the glomerular filtrate.

Transcellular pathway: Reabsorbed amino acids exit the cell via basolateral transporters and enter the bloodstream.

Exchange mechanism: The system operates as an exchanger, using the gradient of neutral amino acids to drive cystine/dibasic amino acid uptake.

Pathophysiology of Cystinuria

Type I cystinuria results from SLC3A1 mutations:

Genetic basis:

• Autosomal recessive inheritance
• Over 150 pathogenic mutations identified
• Frameshift, nonsense, and splice-site mutations common
• Missense mutations often affect trafficking or disulfide bonding

• Recurrent kidney stones (cystine calculi)
• Urinary cystine concentrations 10-20x normal
• Stone formation begins in childhood or adolescence
• Flank pain, hematuria, urinary obstruction

• High fluid intake to maintain dilute urine
• Alkalinization of urine (increases cystine solubility)
• Cystine-binding medications (tiopronin, penicillamine)
• Dietary sodium restriction
• Stone removal procedures when necessary

Amino Acid Transport and the Brain

Blood-Brain Barrier Transport

While SLC3A1 itself is not highly expressed in the brain, the broader system of amino acid transporters is crucial for brain function:

Essential amino acid transport:

• Large neutral amino acid transporter (LAT1, SLC7A5) at the BBB
• Provides brain access to amino acids needed for neurotransmitter synthesis
• Dysregulation contributes to neurodegenerative processes

• Tryptophan, tyrosine, phenylalanine uptake for serotonin and catecholamine synthesis
• Impaired transport may affect neurotransmitter levels in disease

Glutamate Transporters

The broader SLC17 family includes vesicular glutamate transporters:

• VGLUT1-3 package glutamate into synaptic vesicles
• Expression in excitatory neurons
• Dysfunction in ALS, Alzheimer's disease

SLC3A1 in Neurodegenerative Context

While direct evidence linking SLC3A1 to neurodegenerative diseases is limited, the broader context of amino acid transport is highly relevant:

Amino Acid Dysregulation in AD/PD

Alzheimer's disease:

• Altered plasma amino acid levels in AD patients
• Impaired BBB amino acid transport in AD
• CSF/plasma amino acid ratios abnormal
• May affect neurotransmitter precursor availability

• Altered tryptophan and tyrosine metabolism
• Reduced levodopa transport across BBB in some patients
• Role of amino acid transporters in L-dopa efficacy

Blood-Brain Barrier Function

The BBB expresses multiple amino acid transporters:

Cystine/Glutamate Exchange (System xc-)

The cystine/glutamate antiporter (system xc-, composed of SLC7A11 and SLC3A2):

• Imports cystine for glutathione synthesis
• Exports glutamate
• Important for antioxidant defense
• Implicated in Parkinson's disease (MPTP toxicity)
• Target for neuroprotective strategies

Therapeutic Implications

Amino Acid Transporter Targeting

While SLC3A1 is not a direct therapeutic target for neurodegeneration:

System xc- modulators:

• Sulfasalazine inhibits cystine uptake (used in cancer therapy)
• Ebselen enhances system xc- function
• Potential for neuroprotection in PD

• LAT1 inhibitors explored for cancer
• Brain delivery of amino acid-based therapeutics

Cystinuria Treatment Implications

For cystinuria patients:

• Long-term stone disease may affect kidney function
• Potential secondary effects on brain through systemic amino acid dysregulation
• Monitoring of systemic amino acid homeostasis

Interaction Network

SLC3A1 interacts with multiple partners:

Clinical Genetics

Cystinuria Genetics

Inheritance: Autosomal recessive

Genotype-phenotype:

• Type I: Homozygous or compound heterozygous SLC3A1 mutations
• Type II: Homozygous SLC7A9 mutations
• Type III: Compound heterozygous SLC3A1/SLC7A9 mutations

Newborn screening: Not routinely performed (no systemic effects at birth)

Variant Interpretation

• Missense variants: Often affect folding or trafficking
• Nonsense/frameshift: Predicted null alleles
• Splice variants: May cause exon skipping or intron retention
• Variants are evaluated using ACMG guidelines

Research Directions

Structure-Function Studies

• Cryo-EM structures of heterodimeric transporters
• Substrate binding site identification
• Transport mechanism elucidation

Therapeutic Development

• Novel cystine-binding agents
• Gene therapy approaches for cystinuria
• Small molecule correctors of trafficking mutants

Neurodegeneration Connections

• Role of amino acid transport in AD/PD pathogenesis
• System xc- as therapeutic target
• BBB amino acid transporter modulation

References

See Also

• [Cystinuria](/diseases/cystinuria)
• [Amino Acid Transporters](/mechanisms/amino-acid-transport)
• [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)
• [System xc-](/mechanisms/system-xc)
• [Glutamate Transporters](/proteins/glutamate-transporters)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Kidney](/organs/kidney)
• [Intestine](/organs/intestine)
• [SLC Family](/proteins/slc-family)